Alkem’s business model encompasses a wide range of therapeutic segments, including anti-infectives, dermatology, and chronic therapies like diabetology and cardiology, supported by a substantial portfolio exceeding 800 brands. This diversified product mix mitigates risk and caters to varied market demands. The company’s operational strength is underpinned by a significant manufacturing footprint, comprising 21 facilities, the majority of which are located in India, providing a cost-competitive production base.
From a market positioning standpoint, Alkem holds a strong standing within the Indian pharmaceutical landscape, consistently ranking among the top players in terms of domestic sales. The company’s growth trajectory has been fueled by organic expansion through investments in manufacturing and research and development, as well as inorganic growth via strategic acquisitions. Alkem’s commitment to R&D underscores its focus on new product development and maintaining a competitive edge. As a publicly listed entity since 2015, Alkem operates with a focus on delivering shareholder value through sustained growth and profitability within the dynamic pharmaceutical sector.
Latest News on ALKEM Laboratories
Alkem Laboratories’ Sarvesh Singh purchases luxurious Mumbai property worth Rs 174 crore, see details
The luxury property market in Mumbai, India’s financial capital, is experiencing a surge in demand, with over Rs 800 crore worth of high-end property deals recorded in February and March alone. Affluent individuals, including business leaders and celebrities, are driving this trend. One notable example is Sarvesh Singh, executive director of Alkem Laboratories, who recently acquired a sea-facing duplex in Bandra’s Supreme ArtHouse for Rs 174 crore. The 12,148 square foot property offers breathtaking views of the Arabian Sea and is considered one of the most expensive home purchases on the Bandra seafront.
This is not Singh’s first major real estate purchase, having bought a 3,413 square foot apartment in Bandra’s Satguru Rendezvous project for Rs 33 crore in 2023. Other members of the Alkem family have also made significant property purchases, including Seema Singh, who bought a penthouse at Lodha Sea Face in Worli for Rs 185 crore in December 2024.
Mumbai’s luxury property market has witnessed several high-value transactions in recent months, including SR Menon Properties LLP’s purchase of a 14,866 square foot apartment for Rs 187 crore in Lodha Sea Face, Amit Rathi’s purchase of a home valued at Rs 89.91 crore in Palais Royale, and Aruna Varma’s purchase of a luxurious apartment in Worli for Rs 68 crore.
The demand for luxury properties in Mumbai is driven by the city’s status as a financial hub and the increasing wealth of its residents. Developers are catering to this demand by building ultra-luxury properties with high-end amenities and stunning views. Sunny Bijlani, Joint Managing Director of Supreme Universal, the developers of Supreme ArtHouse, noted that the company’s focus on ultra-luxury properties has paid off, with the recent sale being the largest of its kind on the Bandra seafront.
Alkem Laboratories, where Sarvesh Singh is an executive director, is a leading Indian pharmaceutical company with a global presence. The company’s success has enabled its executives to invest in luxury properties, contributing to the growth of Mumbai’s high-end property market. Overall, the luxury property market in Mumbai is expected to continue to thrive, driven by the city’s economic growth and the increasing demand for high-end properties.
Alkem Laboratories has finalized the purchase of a 100% ownership stake in Adroit Biomed.
Alkem Laboratories, a leading pharmaceutical company, has successfully completed the acquisition of a 100% stake in Adroit Biomed, a biotechnology company. This strategic move is expected to strengthen Alkem’s presence in the biotechnology sector and expand its product portfolio.
Adroit Biomed is a research-based organization that focuses on developing innovative products and solutions for various therapeutic areas. The company has a strong research and development pipeline, with several products in different stages of development. With this acquisition, Alkem Laboratories will gain access to Adroit Biomed’s research capabilities, product portfolio, and expertise in biotechnology.
The acquisition is expected to enhance Alkem’s competitiveness in the global pharmaceutical market and provide new opportunities for growth. Alkem Laboratories has been expanding its product portfolio and capabilities through strategic acquisitions and partnerships. This acquisition is a significant step towards achieving the company’s goal of becoming a leading player in the biotechnology sector.
The terms of the acquisition were not disclosed, but it is expected to be completed in a phased manner. Alkem Laboratories will integrate Adroit Biomed’s operations and personnel into its existing business, with the aim of maximizing synergies and minimizing disruptions.
The acquisition of Adroit Biomed is part of Alkem Laboratories’ strategy to expand its presence in the biotechnology sector and to diversify its product portfolio. The company has been investing heavily in research and development and has established partnerships with various organizations to develop new products and technologies.
The completion of this acquisition is a significant milestone for Alkem Laboratories and is expected to have a positive impact on the company’s future growth and profitability. With the acquisition of Adroit Biomed, Alkem Laboratories has strengthened its position in the biotechnology sector and is well-positioned to capitalize on the growing demand for biotechnology products and services.
The acquisition is also expected to benefit Adroit Biomed’s employees, customers, and partners, as it will provide them with access to Alkem Laboratories’ global network, resources, and expertise. Overall, the acquisition of Adroit Biomed by Alkem Laboratories is a strategic move that is expected to drive growth, innovation, and success for both companies.
Biosimilar denosumab, Alkem’s Denuril, Demonstrates Comparable Efficacy in Treating Postmenopausal Osteoporosis
A recent study has demonstrated that Biosimilar Denosumab (Denuril), manufactured by Alkem, is comparable in efficacy to the original Denosumab in treating postmenopausal osteoporosis. Denosumab is a monoclonal antibody that helps to prevent bone loss by inhibiting the activity of osteoclasts, which are cells that break down bone. It is commonly used to treat osteoporosis in postmenopausal women.
The study, published in the Journal of Bone and Mineral Research, involved 354 postmenopausal women with osteoporosis who were randomized to receive either Biosimilar Denosumab (Denuril) or the original Denosumab. The participants received 60mg of the study drug every six months for one year.
The results of the study showed that both Biosimilar Denosumab (Denuril) and the original Denosumab significantly increased bone density in the spine and hip, and reduced the risk of vertebral fractures, a common complication of osteoporosis. The efficacy of the two medications was comparable, with no significant differences observed between the two groups.
The study also found that both medications were well tolerated, with similar levels of adverse events reported in both groups. The most common side effects were mild and included injection site reactions, pain, and infections.
The authors of the study concluded that Biosimilar Denosumab (Denuril) is a viable option for the treatment of postmenopausal osteoporosis, offering similar efficacy and safety to the original Denosumab. This could lead to cost savings and increased access to treatment for patients, making it a valuable addition to the treatment options for osteoporosis.
Overall, the study provides reassuring evidence for the use of Biosimilar Denosumab (Denuril) in the treatment of postmenopausal osteoporosis, and supports its adoption as a viable alternative to the original Denosumab.
Alkem Labs completes inspection process at Taloja Center
The article reports that Alkem Labs, a leading generic pharmaceutical company, has concluded an inspection at its Taloja Center facility. The inspection was conducted by the United States Food and Drug Administration (USFDA). The purpose of the inspection was to verify and assess the compliance of Alkem Labs’ manufacturing facilities, processes, and testing procedures with the current Good Manufacturing Practices (cGMPs) guidelines.
The inspection, which took place over a period of several days, aimed to ensure that Alkem Labs’ Taloja Center facility is adhering to the highest standards of quality, safety, and efficacy in the production and testing of pharmaceutical products. The inspectors assessed various aspects of the company’s operations, including the manufacturing, processing, and testing of its products, as well as the company’s record-keeping and documentation practices.
The inspection is a significant milestone for Alkem Labs, as it demonstrates the company’s commitment to ensuring the quality and safety of its products, as well as its compliance with international regulatory standards. Alkem Labs has built a strong reputation for its high-quality products and robust manufacturing processes, and this inspection is a further testament to its dedication to quality and customer satisfaction.
The outcome of the inspection is still pending, but Alkem Labs has reported that it has “full co-operation and support” from the USFDA during the inspection process. This suggests that the company is committed to working closely with the regulatory authorities to ensure its compliance and to address any issues that may arise.
In conclusion, the inspection by the USFDA at Alkem Labs’ Taloja Center facility is an important step towards ensuring the quality and safety of the company’s products. As a leading generic pharmaceutical company, Alkem Labs has a significant responsibility to its customers, patients, and regulatory authorities to maintain the highest standards of quality and compliance. This inspection is a crucial step in upholding that responsibility.
Alkem Laboratories’ Bioequivalence Center achieves clean record with US FDA inspection, passing with zero observations.
Alkem Laboratories, a leading pharmaceutical company in India, has announced that its Bioequivalence Center has successfully cleared a inspection by the United States Food and Drug Administration (USFDA) without any observations. This achievement is a significant milestone for the company, demonstrating its commitment to maintaining the highest standards of quality and regulatory compliance.
The USFDA inspection was conducted to ensure that Alkem’s Bioequivalence Center, which is responsible for testing and evaluating the bioequivalence of pharmaceutical products, meets the regulatory requirements of the FDA. The inspection covered various aspects, including the center’s infrastructure, equipment, processes, and personnel.
Alkem Laboratories’ Bioequivalence Center is equipped with state-of-the-art facilities and cutting-edge technology, enabling it to conduct complex bioequivalence studies for a wide range of pharmaceutical products. The center is staffed by a team of experienced professionals who are well-versed in the latest regulatory requirements and industry best practices.
The successful inspection by the USFDA is a testament to the center’s ability to maintain high-quality standards and adhere to regulatory guidelines. This achievement is a significant boost to the company’s reputation and allows it to offer its services to clients in the pharmaceutical industry with confidence.
Alkem Laboratories is committed to sustaining its reputation for quality and compliance, and this achievement is a reflection of its dedication to meeting the stringent requirements of the USFDA. The company’s Bioequivalence Center has been recognized for its expertise and capabilities, and this inspection success is a major milestone in its journey to become a leading provider of bioequivalence testing services in the global pharmaceutical industry.
The news is a significant development for Alkem Laboratories, which has been working to expand its presence in the global pharmaceutical industry. The company has been making concerted efforts to invest in its research and development capabilities, as well as its manufacturing infrastructure, to meet the growing demand for high-quality pharmaceutical products.
In conclusion, Alkem Laboratories’ Bioequivalence Center’s successful inspection by the USFDA without any observations is a significant achievement, demonstrating the company’s commitment to quality and regulatory compliance. This achievement is likely to enhance the company’s reputation and credibility in the pharmaceutical industry, and it is expected to open up new opportunities for the company to expand its offerings and reach new markets.
Stock Market Updates for ALKEM Laboratories
Recent Updates
India sees a significant decrease in the price of a commonly used diabetes medication following the introduction of generic alternatives.
The price of the diabetes drug empagliflozin, also known as Jardiance, has been significantly reduced by almost one-tenth in India. The drug, developed by German pharma giant Boehringer Ingelheim, is used to control blood sugar levels in patients with type 2 diabetes. The original price of the drug was around Rs 60 per tablet, but with the entry of its generic versions in the market, it is now available for as low as Rs 5.5 per tablet.
Mankind, Alkem, and Glenmark Pharmaceuticals have launched generic versions of empagliflozin, with prices starting from Rs 5.49 per tablet for the 10 mg variant. These prices are nearly 80% lower than the original price of the innovator product. The generic versions of the drug come with additional features, such as anti-counterfeit security bands, patient education information, and QR codes that provide prescribing information and additional patient education.
The launch of these generic versions of empagliflozin is a significant step in making the drug more affordable for millions of Indians who are suffering from type 2 diabetes. India is known as the diabetes capital of the world, with over 10 crore people diagnosed with the disease, according to the Indian Council of Medical Research–India Diabetes (ICMR INDIAB) study in 2023. Reducing the cost of anti-diabetes medicines like empagliflozin is a crucial step in tackling the disease burden in the country.
Sikkim Governor Unveils Community Hall in Pakyong, Flags Off Sulabh Alkem Award 2024
The Sulabh Alkem Award 2024 ceremony was held at the Integrated Multipurpose Hall in Pakyong, Sikkim, where Governor Om Prakash Mathur attended as the chief guest. The event recognized the outstanding contributions of individuals and institutions to sanitation and hygiene under Project AagazPlus, an initiative aimed at promoting accessible and hygienic sanitation in schools, with a focus on girls’ education and empowerment. The project integrates hygiene improvement in schools through practices such as handwashing with soap, access to clean drinking water, and use of improved sanitation facilities.
Governor Mathur emphasized the importance of hygiene and sanitation, praising the Sulabh Sanitation Club and Alkem Foundation for their efforts in introducing Project AagazPlus to schools. He highlighted the need for initiatives that foster healthier lifestyles among students. The Governor also inaugurated the Integrated Multipurpose Community Hall, a CSR project by the Airports Authority of India.
The event featured testimonials from various stakeholders, including students and teachers, who shared their positive experiences with the project. The Sulabh Alkek Award 2024 recognized schools, teachers, and volunteers for their outstanding work in promoting WASH (water, sanitation, and hygiene) initiatives under Project AagazPlus. Some of the award winners included Government Secondary School, Dalapchand, and teachers Ruchi Thapa, Aquino Sharma, Karma Kunsang Tamang, and Santosh Chettri. The awards also recognized volunteers Ayesha Khatun, Ayogita Sharma, and Ayush Thapa.
Overall, the event aimed to promote better hygiene and sanitation practices in schools, and the importance of girls’ education and empowerment. The award ceremony also acknowledged the efforts of various stakeholders, including the Sulabh Sanitation Club, Alkem Foundation, and the Education Department, in promoting WASH initiatives in schools.
This popular diabetes medication is set to get a significant price cut, dropping from Rs 60 to just Rs 9 per unit.
The cost of Empagliflozin, a crucial drug for managing diabetes and its associated conditions, is set to drop significantly in India. The price of the medicine, which was previously around Rs 60 per tablet, will be reduced to just Rs 9 per tablet, making it more accessible to millions of diabetes patients in the country. This development comes after the patent for the drug, which was previously held by German pharmaceutical company Boehringer Ingelheim, expired on March 11.
As a result, Indian pharmaceutical companies such as Mankind Pharma, Torrent, Alkem, Dr. Reddy, and Lupin will be able to introduce their own versions of the drug, offering patients cheaper alternatives. Mankind Pharma, for example, plans to offer the drug at a price 90% lower than the innovator company, making it more affordable for patients.
Empagliflozin plays a crucial role in preventing heart failure and delaying kidney failure, making it a vital medication for those with diabetes. However, its high cost has previously made it difficult for many to access. The introduction of more affordable options from Indian companies is expected to bring significant benefits to millions of patients.
The reduced price of Empagliflozin is poised to provide much-needed financial relief to diabetes patients, who often face the burden of out-of-pocket medication expenses. In India, over 10.1 crore people are living with diabetes, and limited insurance coverage often leaves patients to shoulder medication costs independently. The availability of more affordable options is expected to make a significant difference in the lives of these patients.
The economic burden of diabetes in India is substantial, and the reduced price of Empagliflozin is a welcome development for diabetic patients across the country. With the introduction of more affordable alternatives, millions of patients will have access to a vital medication, allowing them to better manage their condition and improve their overall health.